| Literature DB >> 35464220 |
Alan Gonçalves Amaral1, Isabela Aparecida Moretto2, Flávia da Silva Zandonadi3, Hans Rolando Zamora-Obando1, Isabela Rocha1, Alessandra Sussulini3,4, André Alexandre de Thomaz5, Regina Vincenzi Oliveira6, Aline Mara Dos Santos2, Ana Valéria Colnaghi Simionato1,4.
Abstract
Cardiovascular diseases (CVDs) are noncommunicable diseases known for their complex etiology and high mortality rate. Oxidative stress (OS), a condition in which the release of free radical exceeds endogenous antioxidant capacity, is pivotal in CVC, such as myocardial infarction, ischemia/reperfusion, and heart failure. Due to the lack of information about the implications of OS on cardiovascular conditions, several methodologies have been applied to investigate the causes and consequences, and to find new ways of diagnosis and treatment as well. In the present study, cardiac dysfunction was evaluated by analyzing cells' alterations with untargeted metabolomics, after simulation of an oxidative stress condition using hydrogen peroxide (H2O2) in H9c2 myocytes. Optimizations of H2O2 concentration, cell exposure, and cell recovery times were performed through MTT assays. Intracellular metabolites were analyzed right after the oxidative stress (oxidative stress group) and after 48 h of cell recovery (recovery group) by ultra-high-performance liquid chromatography coupled to mass spectrometry (UHPLC-MS) in positive and negative ESI ionization mode. Significant alterations were found in pathways such as "alanine, aspartate and glutamate metabolism", "glycolysis", and "glutathione metabolism", mostly with increased metabolites (upregulated). Furthermore, our results indicated that the LC-MS method is effective for studying metabolism in cardiomyocytes and generated excellent fit (R2Y > 0.987) and predictability (Q2 > 0.84) values.Entities:
Keywords: LC-MS; cardiovascular diseases; cell culture; metabolomics; oxidative stress
Year: 2022 PMID: 35464220 PMCID: PMC9023746 DOI: 10.3389/fchem.2022.836478
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.545
Elution gradient of the chromatographic methods. B: Acetonitrile + 0.1% formic acid.
| RPLC-MS (ESI+) and (ESI-) | HILIC-MS (ESI+) and (ESI-) | ||
|---|---|---|---|
| Time (min) | B (%) | Time (min) | B (%) |
| 0 | 1 | 0 | 99 |
| 3 | 2 | 3 | 98 |
| 10 | 20 | 10 | 70 |
| 15 | 60 | 15 | 40 |
| 18 | 85 | 18 | 15 |
| 20 | 90 | 20 | 10 |
| 25 | 95 | 20,1 | 1 |
| 30 | 95 | 22 | 1 |
| 31 | 99 | 22,1 | 99 |
| 33 | 99 | 25 | 99 |
| 33,1 | 1 | ||
| 35 | 1 | ||
FIGURE 1Immunofluorescence images from H9c2 cardiomyocytes after oxidative stress and different recovery times. (A,B) SR-SIM microscopy of cardiomyocytes from Control (CT), oxidative stress (OS), and 24- and 48-h recovery groups. Magenta: actin; Yellow: paxillin; Cyan: γH2Ax; Blue: nucleus. Scale bar = 15 µm.
FIGURE 2(A) PCA for control (red), oxidative stress (green), recovery (light blue), and QCs (blue) samples for RPLC-ESI(+)-MS, RPLC-ESI(−)-MS, HILIC-ESI(+)-MS, and HILIC-ESI(−)-MS modes, from top to bottom. (B) PLS-DA score plot for control (red), oxidative stress (green), and recovery (blue) samples for RPLC-ESI(+)-MS, RPLC-ESI(−)-MS, HILIC-ESI(+)-MS, and HILIC-ESI(−)-MS modes, from top to bottom.
R2Y, Q2, and permutation (p) values for the evaluation of statistical significance.
| R2Y | Q2Y | Permutation test ( | |
|---|---|---|---|
| RPLC-ESI(+)-MS | 0.9915 | 0.8405 | <5 × 10–4 |
| RPLC-ESI(−)-MS | 0.9952 | 0.8428 | <5 × 10–4 |
| HILIC-ESI(+)-MS | 0.9871 | 0.8847 | 0.011 |
| HILIC-ESI(−)-MS | 0.9995 | 0.8855 | 0.0335 |
Statistically significant metabolic pathways (p value < 0.05) altered in H9c2 cardiomyocytes upon H2O2-induced oxidative stress. *p value < 0.01.
| Pathways (OS vs. Control) |
| FDR | Impact | Metabolites up | Metabolites down |
|---|---|---|---|---|---|
| Alanine, aspartate, and glutamate metabolism | 6.7111·10–5 | 0.0056 | 0.4070 | 4 (21.05%) | 1 (14.29%) |
| Pyrimidine metabolism | 3.4662·10–4 | 0.0146 | 0.0912 | 2 (10.53%) | 3 (42.86%) |
| Arginine biosynthesis | 0.0014 | 0.0378 | 0.1168 | 2 (10.53%) | 1 (14.29%) |
| Sphingolipid metabolism | 0.0046 | 0.0958 | 0.0284 | 3 (15.79%) | 0 (0.00%) |
| Aminoacyl-tRNA biosynthesis | 0.0073 | 0.1232 | 0.1667 | 4 (21.05%) | 0 (0.00%) |
| Purine metabolism | 0.0210 | 0.2940 | 0.0230 | 2 (10.53%) | 2 (28.57%) |
| Histidine metabolism | 0.0281 | 0.3373 | 0.0902 | 2 (10.53%) | 0 (0.00%) |
|
|
|
|
|
|
|
| Alanine, aspartate and glutamate metabolism | 1.915·10–5 | 0.0016 | 0.6691 | 7 (17.07%) | 0 (0.00%) |
| Pyrimidine metabolism | 0.0013 | 0.0561 | 0.0963 | 3 (7.32%) | 3 (75.00%) |
| Cysteine and methionine metabolism | 0.0037 | 0.0841 | 0.1220 | 5 (12.20%) | 0 (0.00%) |
| Aminoacyl-tRNA biosynthesis | 0.0040 | 0.0841 | 0.1667 | 5 (12.20%) | 1 (25.00%) |
| Arginine biosynthesis | 0.0095 | 0.1536 | 0.1168 | 3 (7.32%) | 0 (0.00%) |
| Histidine metabolism | 0.0139 | 0.1536 | 0.0492 | 3 (7.32%) | 0 (0.00%) |
| Nitrogen metabolism | 0.0146 | 0.1536 | 0.0 | 2 (4.88%) | 0 (0.00%) |
| D-Glutamine and D-glutamate metabolism | 0.0146 | 0.1536 | 0.5 | 2 (4.88%) | 0 (0.00%) |
| Glyoxylate and dicarboxylate metabolism | 0.0189 | 0.1767 | 0.0741 | 2 (4.88%) | 0 (0.00%) |
| Sphingolipid metabolism | 0.0294 | 0.2469 | 0.0284 | 3 (7.32%) | 0 (0.00%) |
| Pentose phosphate pathway | 0.0385 | 0.2942 | 0.1126 | 3 (7.32%) | 0 (0.00%) |
| Glycolysis/Gluconeogenesis* | 0.0590 | 0.4131 | 0.0425 | 3 (7.32%) | 0 (0.00%) |
|
|
|
|
|
|
|
| Glutathione metabolism | 0.0036 | 0.2425 | 0.3199 | 0 (0.00%) | 3 (60.00%) |
| Cysteine and methionine metabolism | 0.0058 | 0.2425 | 0.0221 | 2 (66.67%) | 1 (20.00%) |
| Sphingolipid metabolism | 0.0235 | 0.6575 | 0.0243 | 1 (33.33%) | 1 (20.00%) |
FIGURE 3Pie chart representation of the statistically significant metabolic pathway present in Table 3 for (A) oxidative stress, (B) recovery, and (C) recovery vs. oxidative stress. The size of the pie chart is represented by the number of up- and downregulated metabolites in each group.
FIGURE 4Representative metabolic pathway maps of significantly altered metabolites. Boxes with dashed lines represent the identified metabolites. Important metabolites related to (A) “Alanine, aspartate and glutamate metabolism” and “Urea cycle”; (B) “Anaerobic glycolysis”; (C) “Pyrimidine biosynthesis”; and (D) “Glutathione metabolism”.